Malinow et al., 1989 - Google Patents
Prevalence of hyperhomocyst (e) inemia in patients with peripheral arterial occlusive disease.Malinow et al., 1989
View PDF- Document ID
- 12568130693139661362
- Author
- Malinow M
- Kang S
- Taylor L
- Wong P
- Coull B
- Inahara T
- Mukerjee D
- Sexton G
- Upson B
- Publication year
- Publication venue
- Circulation
External Links
Snippet
A micromethod adapted for automated determinations was used to measure basal plasma levels of homocyst (e) ine [H (e)]. These levels included the sum of free and bound forms of homocysteine, its disulfide oxidation product, homocystine, and the homocysteine-cysteine …
- 206010062585 Peripheral arterial occlusive disease 0 title abstract description 58
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Malinow et al. | Prevalence of hyperhomocyst (e) inemia in patients with peripheral arterial occlusive disease. | |
| Nehler et al. | Homocysteinemia as a risk factor for atherosclerosis: a review | |
| Coull et al. | Elevated plasma homocyst (e) ine concentration as a possible independent risk factor for stroke. | |
| Maxwell et al. | Antioxidant status in patients with uncomplicated insulin‐dependent and non‐insulin‐dependent diabetes mellitus | |
| Ubbink et al. | Hyperhomocysteinemia and the response to vitamin supplementation | |
| Himmelfarb et al. | The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia | |
| Mansoor et al. | Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease: homocysteine and peripheral vascular disease | |
| Beisswenger et al. | Metformin reduces systemic methylglyoxal levels in type 2 diabetes. | |
| Ubbink et al. | Effective homocysteine metabolism may protect South African blacks against coronary heart disease | |
| Babidge et al. | Sulfides impair short chain fatty acid β-oxidation at acyl-CoA dehydrogenase level in colonocytes: implications for ulcerative colitis | |
| Joosten et al. | Metabolic evidence that deficiencies of vitamin B− 12 (cobalamin), folate, and vitamin B− 6 occur commonly in elderly people | |
| Suliman et al. | Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients | |
| Malinow | Homocyst (e) ine and arterial occlusive diseases | |
| Malinow | Hyperhomocyst (e) inemia. A common and easily reversible risk factor for occlusive atherosclerosis. | |
| Allard et al. | Lipid peroxidation during n− 3 fatty acid and vitamin E supplementation in humans | |
| Mansoor et al. | Dynamic relation between reduced, oxidized, and protein-bound homocysteine and other thiol components in plasma during methionine loading in healthy men | |
| Ueland et al. | Plasma homocysteine and cardiovascular disease | |
| Robinson et al. | Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations | |
| Kang et al. | Protein-bound homocyst (e) ine. A possible risk factor for coronary artery disease. | |
| Piolot et al. | Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health | |
| Mendis et al. | Association between hyperhomocysteinaemia and hypertension in Sri Lankans | |
| Sinatra et al. | Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage | |
| Selley | A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease | |
| Jackson et al. | Synthesis of erythrocyte glutathione in healthy adults consuming the safe amount of dietary protein | |
| Gwilt et al. | The effect of garlic extract on human metabolism of acetaminophen. |